Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women

Mary H Latka, Katherine Fielding, Glenda E Gray, Linda-Gail Bekker, Maphoshane Nchabeleng, Koleka Mlisana, Tanya Nielson, Surita Roux, Baningi Mkhize, Matsontso Mathebula, Nivashnee Naicker, Guy de Bruyn, James Kublin, Gavin J Churchyard, HVTN 503 Phambili study team, Mary H Latka, Katherine Fielding, Glenda E Gray, Linda-Gail Bekker, Maphoshane Nchabeleng, Koleka Mlisana, Tanya Nielson, Surita Roux, Baningi Mkhize, Matsontso Mathebula, Nivashnee Naicker, Guy de Bruyn, James Kublin, Gavin J Churchyard, HVTN 503 Phambili study team

Abstract

Background: HIV prevention trials are increasingly being conducted in sub-Saharan Africa. Women at risk for HIV are also at risk of pregnancy. To maximize safety, women agree to avoid pregnancy during trials, yet pregnancies occur. Using data from the HVTN 503/"Phambili" vaccine trial, we report pregnancy incidence during and after the vaccination period and identify factors, measured at screening, associated with incident pregnancy.

Methods: To enrol in the trial, women agreed and were supported to avoid pregnancy until 1 month after their third and final vaccination ("vaccination period"), corresponding to the first 7 months of follow-up. Unsterilized women, pooled across study arms, were analyzed. Poisson regression compared pregnancy rates during and after the vaccination period. Cox proportional hazards regression identified associations with first pregnancy.

Results: Among 352 women (median age 23 yrs; median follow-up 1.5 yrs), pregnancy incidence was 9.6/100 women-years overall and 6.8/100 w-yrs and 11.3/100 w-yrs during and after the vaccination period, respectively [Rate Ratio = 0.60 (0.32-1.14), p = 0.10]. In multivariable analysis, pregnancy was reduced among women who: enrolled at sites providing contraception on-site [HR = 0.43, 95% CI (0.22-0.86)]; entered the trial as injectable contraceptive users [HR = 0.37 (0.21-0.67)] or as consistent condom users (trend) [HR = 0.54 (0.28-1.04)]. Compared with women with a single partner of HIV-unknown status, pregnancy rates were increased among women with: a single partner whose status was HIV-negative [HR = 2.34(1.16-4.73)] and; 2 partners both of HIV-unknown status [HR = 4.42(1.59-12.29)]. Women with 2 more of these risk factors: marijuana use, heavy drinking, or use of either during sex, had increased pregnancy incidence [HR = 2.66 (1.24-5.72)].

Conclusions: It is possible to screen South African women for pregnancy risk at trial entry. Providing injectable contraception for free on-site and supporting consistent condom use may reduce incident pregnancy. Screening should determine the substance use, partnering, and HIV status of both members of the couple for both pregnancy and HIV prevention.

Trial registration: SA National Health Research Database DOH-27-0207-1539; Clinicaltrials.gov NCT00413725.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. Skoler S, Peterson L, Cates W. Our current microbicide trials: Lessons learned and to be learned Microbicide Q. 2006;1:1–6.
    1. Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana PLoS One. 2007;2:1312.
    1. Raymond EG, Taylor D, Cates W, Tolley EE, Borasky D, et al. Pregnancy in effectiveness trials of HIV prevention agents Sex Transm Dis. 2007;34:1035–1039.
    1. Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial Lancet. 2007;370:251–261.
    1. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos M, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial The Lancet. 2008;372:1977–1987.
    1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide for the prevention of HIV infection in women Science. 2011;329:1168–1174.
    1. Reid SE, Dai JY, Wang J, Sichalwe BN, Akpomiemie G, et al. Pregnancy, contraceptive use, and HIV acquisition in HPTN039: Relevance for HIV prevention trials among African women JAIDS. 2010;53:606–613.
    1. Halpern V, Lie CC, Felblum P, VanDamme L. Predictors of pregnancy in microbicide trials Contraception. 2011;83:436–440.
    1. Cao H, Kaleebu P, Horn D, Flores J, Agrawal D, et al. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: Results of the HIV Network for Prevention Trials 007 Vaccine Study. J Infec Dis. 2003;187:887–895.
    1. Kibuuka H, Guwatudde D, Kimutai R, Maganga L, Maboko L. Contraceptive use in women enrolled into preventive HIV vaccine trials: experience form a phase I/II trial in East Africa PLoS ONE. 2009;4:1–6.
    1. Pitisuttithum P, Rerks-Ngarm S, Kaewkungwal I, Nitayaphan S, Khamboonruang C, et al. Recruitment, retention and participation impact events among women participating in phase III community trial in Thailand AIDS Vaccine Conference, Paris France. Poster abstract #. 2009;193
    1. Rerks-Ngarm S, Pitisuttitithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand New Eng J Med. 2009;361:1–12.
    1. Sibeko S, Baxter C, Yende N, Abdool Karim Q, Abdool Karim SS. Contraceptive Choices, Pregnancy Rates and Outcomes in a Microbicide Trial Obstet Gynecol. 2011;118:895–904.
    1. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study Lancet Infect Dis. 2011;11:507–515.
    1. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Robin Mogg R, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial Lancet. 2008;372:1881–1893.
    1. Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, et al. The value of site preparedness studies for future implementation of phase 2/Ilb/Ill HIV prevention trials: Experience from the HPTN 055 Study JAIDS. 2008;47:93–100.
    1. Vallely A, Hambleton IR, Kasindi S, Knight L, Francis SC, et al. Are women who work in bars, guesthouses and similar facilities a suitable study population for vaginal microbicide trials in Africa? PLoS One. 2010;5:1–9.
    1. Bello B, Kielkowski D, Heederik D, Wilson K. Time-to-pregnancy and pregnancy outcomes in a South African population BMC Pub Health. 2010;10:565.
    1. Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, et al. Cape Town: HSRC Press; 2009. South African national HIV prevalence, incidence, behaviour and communication survey 2008: A turning tide among teenagers?

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner